The FDA recently released a draft guidance document that provided an overview of the content and format of information sponsors should include in the “Indications and Usage” section of a drug label for drugs and biologics.
The FDA recently released a draft guidance document that provided an overview of the content and format of information sponsors should include in the “Indications and Usage” section of a drug label for drugs and biologics.
The document, entitled “Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products—Content and Format,” will apply to the Indications and Usage section for new drugs as well as new indications, or if the label of an already approved drug needs to be revised.
“The indications and usage section should clearly communicate the scope of the approved indication, including the population to which the determination of safety and effectiveness is applicable… In some cases, FDA’s expert reviewers may fairly and responsibly conclude, based on their scientific training and experience, that the available evidence supports approval of an indication that is broader or narrower in scope than the precise population studied,” the document reads.
In addition, the guidance discusses circumstances where it “may be appropriate to consider an indication for an adult population in an age group broader than the population that was studied.” This approach, however, is generally not applicable across pediatric populations or between adult and pediatric populations due to the Pediatric Research Equity Act.
The guidance is part of a series of guidances that the agency has put out or is developing in order to assist developers with the content and format of labeling for drug and biological products.
“FDA-approved labeling is the primary communication tool for providing information on the safe and effective use of drugs to the medical community,” Jacqueline Corrigan-Curay, MD, JD, director of the Office of Medical Policy in FDA’s Center for Drug Evaluation and Research, said in a statement. “This guidance provides recommendations for drafting the Indications and Usage section of the labeling, including a discussion of the scope of an indication and the inclusion of age groups in indications. We believe this guidance will help healthcare providers identify appropriate treatment options for their patients.”
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.